 |
|
|
| |
Effects of Low and High Mineral Water Content on the Relative Bioavailability of a Co-Formulated TRIUMEQ (Abacavir/Dolutegravir/Lamivudine) Dispersible Tablet in Healthy Adults
|
| |
| |
Reported by Jules Levin
19th International Workshop on Clinical Pharmacology of Antiviral Therapy; May 22-24,
2018; Baltimore, MD
Jafar Sadik B. Shaik,1Kimberly Adkison,2Nancy Skoura,1Shashidhar Joshi,3Trevor Shreeves,4Linda Casillas,1Ann M. Buchanan,2Rajendra P. Singh1
1GlaxoSmithKline, Collegeville, PA; 2ViiV Healthcare, Research Triangle Park, NC; 3GlaxoSmithKline, Bangalore, India; 4GlaxoSmithKline, Ware, Hertfordshire, UK
|
| |
|
|
|
|
|
